Immunome, Inc. (NASDAQ: IMNM) announced it has entered into a definitive securities purchase agreement for the sale of its equity securities in a private placement with certain accredited investors for gross proceeds to Immunome of approximately $27 million, before deducting placement agent commissions and other offering expenses. The agreement provides for the sale of an aggregate of 1,000,000 units at a price of $27.00 per unit. Each unit consists of one share of Immunome's common stock and a warrant to purchase one half of a share of common stock at an exercise price of $45.00. Immunome intends to use the net proceeds to accelerate the development of its oncology and infectious disease portfolio, including COVID-19, and for other general corporate purposes.
Additional details regarding the private placement are included in a Form 8-K, which has been filed by Immunome with the Securities and Exchange Commission ("SEC"). Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent in connection with the offering.
About Immunome
Immunome, Inc. (NASDAQ: IMNM) is a biopharmaceutical company that utilizes its proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics that are designed to change the way diseases are treated. The company's initial focus is on developing therapeutics to treat oncology and infectious diseases, including COVID-19. Immunome's proprietary discovery engine identifies novel therapeutic antibodies and their targets by leveraging the highly educated components of the immune system, memory B cells, from patients whose bodies have learned to fight off their disease. For more information, please visit www.immunome.com.
The information and material presented is provided for informational purposes only and are not to be used or considered as an offer or the solicitation of an offer to sell or buy any securities mentioned herein.